Are New DES Designs Safer?
|
|
- Abigayle Bradford
- 5 years ago
- Views:
Transcription
1 cit0711_f6_krucoff.qxd 8/24/11 2:03 PM Page 56 Are New DES Designs Safer? Changes in stent platform, polymer, and drug components have led to improved outcomes. BY ASHWANI SASTRY, MD, AND MITCHELL W. KRUCOFF, MD, FACC, FSCAI, FAHA Drug-eluting stents (DES) are combination products traditionally consisting of three components (platform, polymer, and drug), each with innumerable potential design permutations (Figure 1). Currently, six DES are available in the United States (Table 1), with more than a dozen additional products being evaluated in clinical trials globally. Design objectives range from improvements in mechanical deliverability and late lumen loss to enhanced endothelial healing and safety. As combination products, however, small changes in one component may interact with other components in unexpected ways, making comparisons among various DES in specific patient populations, lesion types, and with differing adjunctive therapies both essential and complex. Because DES are permanent coronary implants used to treat millions of patients, rare but catastrophic safety events, such as stent thrombosis (ST), have emerged as public health concerns shared by clinicians, manufacturers, regulatory authorities, and the public. Evaluation of such endpoints requires large cohorts, long followup, and at least some randomized data, making safety comparisons of new DES an ongoing challenge. In this article, we examine the degree to which changes in Figure 1. DES are complex combination products employing a base stent material, scaffold architecture, polymer coating, and drug. 56 ICARDIAC INTERVENTIONS TODAYIJULY/AUGUST 2011
2 cit0711_f6_krucoff.qxd 8/24/11 2:03 PM Page 57 TABLE 1. DESIGN SPECIFICATIONS OF THE SIX DES THAT ARE CURRENTLY FDA APPROVED Stent Drug (µg/cm 2 ) Polymer Polymer Thickness (µm) Drug Release, (28 d) Metal Geometry Strut Thickness (µm) Cypher Sirolimus (140) Durable % SS Closed cell 140 Taxus Express Paclitaxel Durable 16 < 10% SS Open cell 132 Taxus Liberté Paclitaxel Durable 16 < 10% SS Hybrid 97 Endeavor Zotarolimus Durable, biocompatible % CoCr Open cell 91 Xience V Everolimus Durable % CoCr Open cell 81 Ion Paclitaxel Durable 15 < 10% PtCr Closed cell 81 Abbreviations: CoCr, cobalt chromium; PtCr, platinum chromium; SS, stainless steel. stent platform, polymer, or drug components have produced clinical data suggesting that new design features achieve their intended objectives. FROM FIRST TO SECOND GENERATION: RAISING THE BAR FOR SAFETY COMPARISON Everolimus-eluting stents (EES) (Xience V, Abbott Vascular, Santa Clara, CA; Promus, Boston Scientific Corporation, Natick, MA) currently are the most studied medical devices in history, with more than 15,000 patients in more than half a dozen randomized clinical trials (RCTs) followed for as long as 4 years. Clinical outcomes in patients treated with Xience V/Promus EES have been reported in progressively more complex patients, head to head against more DES platforms, and with longer followup periods than any other stent. The consistency of cumulative Xience V/Promus EES data support the contention that DES technology can produce both low late loss and very low ST, setting a pragmatic bar for comparison as new platforms emerge. Recently published 2-year follow-up data of the SPIRIT IV 1 and COMPARE 2 studies show superiority of Xience V/Promus EES to the paclitaxel-eluting (PES) Taxus Express and Taxus Liberté stents (Boston Scientific Corporation), respectively. In the SPIRIT IV study, 3,687 patients with up to three noncomplex, previously untreated lesions were randomized to Xience V/Promus EES or Taxus Express PES. Two-year results uniformly favored EES: target lesion failure (TLF) (6.9% vs 9.9%; P =.003), myocardial infarction (MI) (2.5% vs 3.9%; P =.02), Q-wave MI (0.1% vs 0.8%; P =.002), ST (0.4% vs 1.2%; P =.008), and ischemiadriven target lesion revascularization (TLR) (4.5% vs 6.9%; P =.004). In the COMPARE all-comers, prospective, double-blind study, 1,800 patients were randomized 1:1 to treatment with Xience V/Promus EES or Taxus Liberté PES. The primary composite endpoint of all death, nonfatal MI, and target vessel revascularization (TVR) occurred in 9% of Xience V/Promus EES patients and in 13.7% of Taxus Liberté PES patients (relative risk [RR]: 0.66; 95% confidence interval [CI], ) driven by a lower rate of MI (3.9% vs 7.5%; RR, 0.52; 95% CI, ) and TVR (3.2% vs 8%; RR, 0.41; 95% CI, ), in parallel with a lower rate of definite or probable ST (0.9% vs 3.9%; RR, 0.23; 95% CI, ). Comparisons of EES to sirolimus-eluting stents (SES) (Cypher, Cordis Corporation, Bridgewater, NJ) include the JULY/AUGUST 2011 I CARDIAC INTERVENTIONS TODAY I 57
3 cit0711_f6_krucoff.qxd 8/24/11 2:03 PM Page 58 Preclinical and observational evidence also suggests that thinner struts may reduce restenosis and facilitate endothelialization. EXCELLENT, ISAR-TEST 4, 3 SORT OUT-4, and BASKET- PROVE 4 trials. ISAR-TEST 4 was an open-label randomized controlled trial (RCT) comparing a novel biodegradable polymer DES to Cypher SES and Xience V/Promus EES. A substudy randomized 1,304 patients with de novo coronary lesions and ischemia (1:1) to Xience V/Promus EES or Cypher SES. At 2 years, the combined endpoint of cardiac death, target vessel MI, or TLR was similar between groups (Cypher SES, 18.8%; Xience V/Promus EES, 16%; P =.23), whereas TLR favored Xience V/Promus EES (Cypher SES, 13.5%; Xience V/Promus EES, 9.9%; P =.06). Definite or probable ST was numerically lower in Xience V/Promus EES, although it was not significant (Cypher SES, 1.9%; Xience V/Promus EES, 1.4%; P =.52). The SORT-OUT 4 single-blind, RCT of Xience V/Promus EES versus Cypher SES in an all-comers population of 2,774 patients demonstrated noninferiority of Xience V/Promus EES to Cypher SES in the combined primary endpoint of major adverse cardiac events (MACE) (Cypher SES, 5.2%; Xience V/Promus EES, 4.9%; P =.01 for noninferiority). The individual components of the combined endpoint were not significantly different between groups, with the exception of definite ST, which was significantly lower in Xience V/Promus EES (Xience V/Promus EES, 0.1%; Cypher SES, 0.7%; P =.05). Lastly, the EXCELLENT study was a prospective, openlabel, 2 X 2 RCT comparing Xience V/Promus EES to Cypher SES, as well as comparing 6 months to 1 year of dual-antiplatelet therapy. In the EXCELLENT study, 1,443 patients with native coronary stenoses > 50% and evidence of myocardial ischemia were randomized 3:1 to Xience V/Promus EES or Cypher SES. In an analysis pooling subgroups treated with 6 months versus 1 year of dualantiplatelet therapy and comparing Xience V/Promus EES to Cypher SES, Xience V/Promus EES was noninferior to Cypher SES in the primary endpoint of in-segment loss at 9 months (Xience V/Promus EES, 0.1 ± 0.36 mm; Cypher SES, 0.05 ± 0.34 mm; P =.023 for noninferiority). Consistent with the SORT-OUT 4 and ISAR-TEST 4 studies, definite or probable ST was numerically lower in the Xience V/Promus EES group (Xience V/Promus EES, 0.4%; Cypher SES, 0.8%; P =.281), although it was not significant. Compared to first-generation PES/SES, the EES was designed with thinner cobalt chromium (CoCr) struts with open-cell geometry, a biocompatible polyvinylidene fluoride based durable polymer, and the -limus analogue everolimus in a low total dose eluted 80% over 28 days. 1 It is intriguing to speculate on whether it is one of these features alone or the combination of all three that has resulted in a large and consistent body of clinical data suggesting that EES represent a true advance over first-generation DES with equivalent or improved efficacy and improved safety. NEW STENT SCAFFOLDS: IS THINNER SAFER? Stent scaffold design variables (such as material, cell length, cell pattern, and strut thickness) continue to have a key role in determining performance, including deliverability, side branch access, and in DES, the surface area for drug delivery. Preclinical and observational evidence also suggests that thinner struts may reduce restenosis and facilitate endothelialization. 5-7 To allow for adequate radial strength and low recoil while reducing strut thickness, many platform designs have moved from stainless steel to CoCr or platinum chromium (PtCr). By virtue of its density, the struts of the PtCr platform are among the thinnest of any current DES. The Ion PES (Boston Scientific Corporation) was recently approved based on the results of the PERSEUS Workhorse 8 and Small Vessel 9 studies. PERSEUS Workhorse was a prospective 3:1 RCT comparing the Ion PES to the Taxus Express PES in de novo coronary lesions. The Ion PES was noninferior to Taxus Express PES in the primary endpoint of 12-month TLF (Ion PES, 5.57%; Taxus Express PES, 6.14%; Bayesian probability for noninferiority, ). No differences in 12-month clinical outcomes were observed. The PERSEUS Small Vessel ( mm) study was a singlearm trial comparing Ion PES to a lesion-matched historical cohort treated with bare-metal stent (BMS). The primary 9-month angiographic late loss endpoint favored Ion PES (0.38 ± 0.51 mm vs 0.80 ± 0.53 mm; P <.001). Conclusions on rare safety endpoints such as ST, MI, and death were limited by study size and follow-up duration. The PtCr scaffold has also been developed with everolimus (Promus Element, Boston Scientific Corporation). In the PLATINUM study, 10 1,530 patients undergoing percutaneous coronary intervention of de novo native coronary lesions were randomized 1:1 to Xience V EES versus Promus Element EES. The primary endpoint of 12-month TLF was not significantly different between groups (Xience V EES, 2.9% vs Promus Element EES, 3.4%; P =.001 for noninferiority), with no significant differences in cardiac death, MI, or ST at 12 months. Whether there is a benefit to reducing strut thickness of DES even further than that achievable with CoCr and PtCr remains unclear. 58 ICARDIAC INTERVENTIONS TODAYIJULY/AUGUST 2011
4 cit0711_f6_krucoff.qxd 8/24/11 2:03 PM Page 59 A B Figure 2. Changes to the bioresorbable vascular scaffold (BVS) to improve vessel wall support. The original BVS design: the red circle indicates the maximal circular unsupported surface area (A). Redesigned BVS: the strut distribution is more uniform, and the maximal circular unsupported surface area (red circle) is significantly decreased (B). Reproduced from Gomez-Lara J, Brugaletta S, Diletti R, et al. A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds. Eur Heart J. 2011;32(3): , by permission of Oxford University Press. POLYMER Polymer allows drug loading onto polished metal stent platforms and also provides control of drug elution. Unintended consequences reported with durable polymer include inflammatory and allergic reactions, incomplete endothelialization, and inhibition of recovery of normal endothelial function, with concerns that such observations relate to long-term DES safety and ST. New DES design changes include use of more biocompatible durable polymers, bioabsorbable polymers with less blood exposure, and polymer-free drug delivery systems. The zotarolimus-eluting stent (ZES) (Endeavor, Medtronic, Inc., Minneapolis, MN) was the first DES available in the United States to use the highly biocompatible, durable phosphorylcholine polymer on a CoCr platform. A meta-analysis of ZES compared to BMS showed comparable ST rates over more than 3 years of follow-up. 14 Late lumen loss, however, was not noninferior to either first-generation Taxus PES 15 or Cypher SES. 16 To improve late lumen loss, the polymer was changed to a blend of three separate durable polymers (BioLinx, Medtronic, Inc.) with differing hydrophobicities, allowing for more sustained drug release past 120 days. Using the same platform, drug, and dose of drug, the shift from Endeavor ZES to Resolute ZES (Endeavor Resolute stent, Medtronic, Inc.) was exclusive to the polymer and the kinetics of drug delivery. In the RESOLUTE US single-arm study 17 of 1,402 patients with de novo coronary lesions treated with Resolute ZES, the primary endpoint of 12-month TLF was numerically lower in the Resolute ZES group than in propensity score matched historical cohorts treated with the Endeavor ZES (Resolute ZES, 3.7%; Endeavor ZES, 6.5%; P <.001 noninferiority). In the RES- OLUTE all-comers study, 18 patients were randomized 1:1 to treatment with Resolute ZES or Xience V/Promus EES. The composite primary endpoint of death, MI, and revascularization did not differ between groups (Resolute ZES, 20.6%; Xience V/Promus EES, 20.5%; P =.958) at 2 years. ST rates, while not significantly different, were almost 50% lower in the Xience V/Promus EES group (Resolute ZES, 1.9%; Xience V/Promus EES, 1%; P =.077). As seen in the transition from Endeavor ZES to Resolute ZES, efficacy can clearly be altered by changing drug-elution kinetics. Whether this change results in new residual safety concerns remains controversial. Shifts away from durable polymers include attempts to minimize polymer exposure by using more directed coatings and bioabsorbable substrates. The BioMatrix Flex biolimus-eluting stent (BES) (Biosensors International, Singapore) employs a polylactic acid (PLA) polymer applied to the abluminal surface. PLA is degraded to lactic acid over approximately 6 months, leaving only the BMS scaffold. Loaded with the novel - limus analogue Biolimus A9 on a stainless steel platform, this DES was tested against Cypher SES in the LEADERS study, 19 a prospective 1:1 RCT of 1,707 all-comers patients. The 9-month primary endpoint of cardiac death, MI, or TVR showed BioMatrix BES was noninferior to Cypher SES with numerical superiority (BioMatrix BES, 9%; Cypher SES, 11%; P =.003 for noninferiority). At 3-year follow-up, 20 major adverse cardiac events trended in favor of BioMatrix BES (BioMatrix BES, 15.7%; Cypher SES, 19%; P =.09), and ST numerically favored BioMatrix BES but was not significant (BioMatrix BES, 2.2%; Cypher SES, 2.9%; P =.43). Head-to-head RCTs against second-generation DES, such as Xience V/Promus EES, have not been reported. JULY/AUGUST 2011 I CARDIAC INTERVENTIONS TODAY I 59
5 cit0711_f6_krucoff.qxd 8/24/11 2:03 PM Page 60 Figure 3. Endothelial progenitor cell capture on the Genous R stent. Although the shift to reduced exposure of a biodegradable polymer in combination with the drug biolimus appears to preserve efficacy, the intuitive potential safety advantage relative to a durable polymer remains unproven. Attempts to eliminate polymer altogether include the use of surface texturing to create microcavities that retain drug applied directly to the metal platform. The BioFreedom BES (Biosensors International) uses such an etched stainless steel scaffold loaded with Biolimus A9. Drug tends to elute in a rapid burst because control of kinetics without polymer is challenging. Animal studies with BioFreedom BES indicate that > 95% of biolimus is eluted from the stent within 28 days. 21 Human data so far are limited, with first-in-man reports of small cohorts showing encouraging late loss compared to PES. 22 Safety events and clinical outcomes in these small cohorts are not interpretable. Thus, whether a polymer-free design with burst drug delivery is safer than a durable biocompatible or bioabsorbable polymer design remains to be seen. DRUG Safety concerns related to inhibitory drugs, such as the - limus analogues (mtor inhibitors) or the microtubule targeting paclitaxel, are unintended inhibition of endothelial recovery, leaving uncovered stent struts as a potential nidus for ST. Local drug toxicity could result from interaction of the dose-response relationship and settings such as overlapping stents or use of the bifurcation crush technique, which double and triple the local dose of drug, respectively. Paclitaxel, with its steep dose-response curve, was likely one factor leading to the relabeling of Taxus PES with cautions for overlapping stents required by the FDA on the basis of safety event rates seen in TAXUS V. 23 Conversely, the low drug load in EES platforms may promote device safety. Two new molecular entities in DES, zotarolimus and biolimus, each have notable features. Zotarolimus in the same dose but with longer delivery kinetics significantly improved late lumen loss, as seen in the case of Endeavor ZES and Resolute ZES. Biolimus is the most lipophilic of the - limus analogues and may behave differently in burst delivery systems, such as the polymer-free BioFreedom BES. Whether either of these agents contributes to improved safety remains to be seen. NOVEL APPROACHES Two novel stent designs with potentially revolutionary safety implications include completely bioresorbable stents and stents using endothelial progenitor cell (EPC) capture technology. The BVS is an EES with a scaffold platform (Abbott Vascular) that consists of a poly-l-lactide backbone coated with poly-d,l-lactide polymer controlling drug release. 24 In the ABSORB cohort A study, 3-year follow-up of 30 patients implanted with BVS showed no ST, but the late loss rate at 6 months was 0.44 mm, leading to a scaffold redesign allowing for more uniform strut distribution (Figure 2). In the ABSORB cohort B study, 24 the redesigned BVS tested in 101 patients with de novo coronary lesions displayed a 6-month angiographic late loss rate of 0.19 mm in 45 patients, comparable to the Xience/Promus EES benchmark. No ST has been reported, but the cohort size is too small to draw meaningful conclusions. Whether treatment with BVS results in restoration of normal endothelial function compared to permanent metal scaffolds, and whether this translates into improved long-term safety, will require further study. Recruiting circulating EPCs to more quickly and completely cover stent struts has two potential mechanistic benefits: (1) downregulation of inflammatory mitotic triggers resulting in lower restenosis and (2) removing the nidus for ST. The Genous R stent (GRS) (OrbusNeich, Fort Lauderdale, FL) employs a polysaccharide matrix onto which murine antihuman-cd34 antibodies are immobilized (Figure 3). Randomized against PES in 193 patients with high-risk lesions, 28 GRS TLR was higher and comparable to BMS platforms (GRS, 17.3%; PES, 10.5%; not significant). ST rates were lower in GRS, but the study was underpowered to ascertain whether this was related to EPC capture or simply consistent with a BMS scaffold. More recently, a GRS DES with an abluminal bioabsorbable polymer-eluting sirolimus has begun clinical trials. With CD34 antibody, the GRS DES platform is the first 60 ICARDIAC INTERVENTIONS TODAYIJULY/AUGUST 2011
6 cit0711_f6_krucoff.qxd 8/24/11 2:03 PM Page 61 four-component DES employing drug, polymer, scaffold, and antibody. Whether more rapid and complete endothelial coverage in this construct will translate into superior early or late safety and ST represents an interesting horizon. CONCLUSION Safety concerns with first-generation Taxus PES and Cypher SES include rare but catastrophic events, such as ST. With second-generation CoCr scaffold Endeavor ZES and Xience/Promus EES and using durable biocompatible polymer, safety has significantly improved. Demonstrating even further benefit of new, safety-oriented modifications will require larger cohorts of more complex patients and lesions followed over longer periods of time. Nonetheless, DES are implanted in more than 1 million patients annually and innovative improvements in scaffolds, polymers, and drugs (and their combinations) continue. Proof of the role of even thinner struts, reduced polymer exposure, bioabsorbable polymers, polymer-free designs, lower drug doses, bioresorbable platforms, and EPC capture and strut coverage in promoting safety remains an exciting, complex, and challenging arena of clinical investigation. Ashwani Sastry, MD, is from the Department of Medicine/Division of Cardiology at Duke University Medical Center in Durham, North Carolina. He has disclosed that he has no financial interests related to this article. Mitchell W. Krucoff, MD, FACC, FSCAI, FAHA, is from the Department of Medicine/Division of Cardiology at Duke University Medical Center in Durham, North Carolina. He has disclosed that he is a paid consultant to and receives grant/researching funding from Abbott Vascular, Biosensors International, Boston Scientific Corporation, Cappella Medical Devices Ltd, Cordis Corporation/Johnson & Johnson, Medtronic Inc., OrbusNeich, and Terumo Interventional Systems. Dr. Krucoff may be reached at (919) ; kruco001@mc.duke.edu. 1. Stone GW, Rizvi A, Sudhir K, et al. Randomized comparison of everolimus- and paclitaxeleluting stents: 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol. 2011;58: Smits PC, Kedhi E, Royaards KJ, et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice COM- PARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: a randomized open label trial). J Am Coll Cardiol. 2011;58: Byrne RA, Kastrati A, Kufner S, et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J. 2009;30: Kaiser C, Galatius S, Erne P, et al. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med. 2010;363: Simon C, Palmaz JC, Sprague EA. Influence of topography on endothelialization of stents: clues for new designs. J Long Term Eff Med Implants. 2000;10: Pache J, Kastrati A, Mehilli J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003;41: Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation. 2001;103: Kereiakes DJ, Cannon LA, Feldman RL, et al. Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) trial. J Am Coll Cardiol. 2010;56: Cannon LA, Kereiakes DJ, Mann T, et al. A prospective evaluation of the safety and efficacy of TAXUS Element paclitaxel-eluting coronary stent implantation for the treatment of de novo coronary artery lesions in small vessels: the PERSEUS Small Vessel trial. EuroIntervention. 2011;6: , Stone GW, Teirstein PS, Meredith IT, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. J Am Coll Cardiol. 2011;57: Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370: Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxeleluting coronary stents. N Engl J Med. 2007;356: Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: a metaanalysis of randomized clinical trials. Am J Med. 2006;119: Mauri L, Massaro JM, Jiang S, et al. Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents. JACC Cardiovasc Interv. 2010;3: Leon MB, Mauri L, Popma JJ, et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol. 2010;55: Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2006;48: Yeung AC, Leon MB, Jain A, et al. Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial. J Am Coll Cardiol. 2011;57: Silber S, Windecker S, Vranckx P, Serruys PW. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet. 2011;377: Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008;372: Serruys P, Windecker S, Marie-Claude M, Buszman P. LEADERS: 3-year follow-up from a prospective, randomized trial of Biolimus A9-eluting stents with a bioabsorbable polymer vs. sirolimus-eluting stents with a durable polymer. J Am Coll Cardiol. 2010;56 (suppl B):B Tada N, Virmani R, Grant G, et al. Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ Cardiovasc Interv. 2010;3: Otake H, Kim B-K, Waseda K, et al. Comparison of polymer-free BioFreedom stents with polymer-based TAXUS Liberte stents: the 4-month intravascular ultrasound results from the Biofreedom first-in-man trial. J Am Coll Cardiol. 2010;56 (suppl B):B Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294: Serruys PW, Onuma Y, Ormiston JA, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation. 2010;122: Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008;371: Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373: Onuma Y, Serruys PW, Ormiston JA, et al. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention. 2010;6: Beijk MA, Klomp M, Verouden NJ, et al. Genous endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. Eur Heart J. 2010;31: JULY/AUGUST 2011 I CARDIAC INTERVENTIONS TODAY I 61
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationPolymer-Free Stent CX - ISAR
Polymer-Free Stent CX - ISAR Moo Hyun Kim, MD, FACC on behalf of Dr. Florian Krackhardt, Germany CX ISAR Stent : Features Intracoronary Stenting and Angiographic Results Strut Thickness of only 50/60 μm
More informationInnovation in Cardiovascular Interventions. New DES, Scaffolds and other Devices Have Angioplasty Results Improved
Innovation in Cardiovascular Interventions New DES, Scaffolds and other Devices Have Angioplasty Results Improved Alexandra Lansky, MD Yale University School of Medicine University College of London DES
More informationVascular Intervention // Coronary Drug-Eluting Stent System. Orsiro. Clinically proven. Highly deliverable. Ultrathin 60 μm struts
Vascular Intervention // Coronary Drug-Eluting Stent System Clinically proven Highly deliverable Ultrathin 60 μm struts The new benchmark for DES BIOFLOW-V 12-month clinical outcomes compared to Xience
More informationBiosensors Lunch Symposium
Are Current DES the Final Answer? BioFreedom TM : the Polymer-Free Biolimus A9TM Coated Stent Biosensors Lunch Symposium 25 th April 2013 Prof. Stephen WL Lee, JP 李偉聯 MD FRCP(Lon. Edin. Glas.) FHKCP FHKAM
More informationNEW GENERATION DES WITH NEW GENERATION POLYMERS. Prof. Dr. Rainer Wessely, Duisburg, Germany
NEW GENERATION DES WITH NEW GENERATION POLYMERS Prof. Dr. Rainer Wessely, Duisburg, Germany Sousa J et al., JACC Cardioasv Interv 2010 10 years DES NEXT DES BMS + DAPT DES DES + DAPT S A F E T Y BMS E
More informationSecond Generation Drug Eluting Stents: From Inhibition to Healing
Second Generation Drug Eluting Stents: From Inhibition to Healing Mitchell W. Krucoff MD, FACC Professor of Medicine / Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke
More informationElement Clinical Program Perseus Late Breaking News and the Platinum Study Design
Element Clinical Program Perseus Late Breaking News and the Platinum Study Design Ian T. Meredith MBBS, BSc(Hons), Ph.D, FRACP, FACC, FCSANZ, FSCAI, FAHA, FAPSIC Professor and Director of Monash HEART
More informationFrom a DES to a BMS* Biosensors Clinical Trial Program. Taking the LEAD in DES Clinical Excellence. From Single de Novo.
Biosensors Clinical Trial Program Taking the LEAD in DES Clinical Excellence Our trials gather clinical data for this technology from a wide range of patients, including those with single de novo lesions,
More informationThe DES Landscape in 2011
The DES Landscape in 2011 Future directions in drug-eluting stent design. BY JEFFREY S. KUNZ, MD, AND MARK A. TURCO, MD, FACC, FSCAI The development of bare-metal stents (BMS) in the late 1980s revolutionized
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationTaking DES technology from concept to long term clinical evidence. Aurore Bouvier Global Product Manager Biosensors Europe
Taking DES technology from concept to long term clinical evidence Aurore Bouvier Global Product Manager Biosensors Europe My conflicts of interest are: Full time employee of Biosensors Europe SA BA9 shows
More informationPCI with Polymer-free Stent
PCI with Polymer-free Stent Florian Krackhardt, M.D. Department of Cardiology Charité Campus Virchow-Klinikum University Hospital Berlin, Germany Drug Eluting Stents: Present Coating Technology Solution
More informationBioresorbable stents for all or for few? Franz-Josef Neumann
Bioresorbable stents for all or for few? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria, consultancy fees and research grants from Lilly, Daiichi Sankyo, Sanofi-Aventis,
More informationMoins de 6 mois d antiagrégants après DES?
Moins de 6 mois d antiagrégants après DES? High Tech - Marseille 25 au 27 janvier 2011 Marie-Claude MORICE, MD, FESC, FACC Massy, France Pas de conflit d interet Was optimal duration of DAPT already established
More information2-Year Patient-Related Versus Stent-Related Outcomes
Journal of the American College of Cardiology Vol. 60, No. 13, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.004
More informationBIOFREEDOM: Polymer free Biolimus A9 eluting
TCTAP 2011 Seoul, April 27 29, 2011 BIOFREEDOM: Polymer free Biolimus A9 eluting Stents and Paclitaxel eluting stents Eberhard Grube MD, FACC, FSCAI Hospital Oswaldo Cruz - Dante Pazzanese, São Paulo,
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationNobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy
Nobori Clinical Studies Up-dates Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy Drug Eluting Stents High benefit in preventing restenosis and improving quality of life
More informationWhat Stent to Use? JASVINDAR SINGH MD, FACC
What Stent to Use? JASVINDAR SINGH MD, FACC ASSOCIATE PROFESSOR OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS DIRECTOR, CARDIAC CATHETERIZATION LAB BARNES-JEWISH HOSPITAL What Stent to Use? Jasvindar
More informationBioresorbable polymer drug-eluting stents in PCI
EARN 3 FREE CPD POINTS CARDIOVASCULAR Leader in digital CPD for Southern African healthcare professionals The BIOFLOW-V trial, using the Orsiro ultrathin strut stent with biodegradable polymer, showed
More informationBiodegradable polymer limus-eluting stents are noninferior to permanent polymer-based stents: the ISAR-TEST-4 trial
Clinical trial report Biodegradable polymer limus-eluting stents are noninferior to permanent polymer-based stents: the ISAR-TEST-4 trial Biodegradable polymer drug-eluting stent (DES) platforms have the
More information2-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice
Journal of the American College of Cardiology Vol. 58, No. 1, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.023
More informationDRUG ELUTING STENTS. Cypher Versus Taxus: Are There Differences? Introduction. Methods SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C.
DRUG ELUTING STENTS Cypher Versus Taxus: Are There Differences? SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C. From the Cardiology Practice and Hospital, Munich, Germany Today, drug-eluting stents (DES) are
More informationSKG Congress, 2015 EVOLVE II. Stephan Windecker
SKG Congress, 2015 EVOLVE II Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland BIODEGRADABLE POLYMER DES Stefanini,
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More informationINDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT...
May 2017 INDEX 1 INTRODUCTION... 2 2 DEVICE DESCRIPTION... 3 ANTI-PROLIFERATIVE DRUG - SIROLIMUS... 3 BIODEGRADABLE POLYMERS... 3 SIROLIMUS CONTROLLED ELUTION... 4 STENT PLATFORM... 4 3 CLINICAL PROGRAM...
More informationResolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Prof. Ran Kornowski, MD, FESC, FACC Director - Division of Interventional Cardiology Rabin Medical Center and Tel Aviv University,
More information3-Year Clinical Outcomes in the Randomized SORT OUT III Superiority Trial Comparing Zotarolimus- and Sirolimus-Eluting Coronary Stents
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 5, NO. 8, 2012 2012 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2012.04.008
More informationDisclosure Eberhard Grube, M.D.
Disclosure Eberhard Grube, M.D. I disclose the following financial relationships: Consultant Sadra Medical, Core Valve, Biosensors, Orbus Neich, Cordis Johnson & Johnson, Boston Scientific, Mitralign,
More informationCYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms. Campbell Rogers, M.D. Chief Technology Officer
Ground breaking, Life changing CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms Campbell Rogers, M.D. Chief Technology Officer Disclosure Statement of Financial Interest I am a full-time
More informationBioabsorbable stents: early clinical results. Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals
Bioabsorbable stents: early clinical results Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals MY CONFLICTS OF INTEREST ARE: Clinical Events Committee member for
More informationClinical Study Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized Trials
Thrombosis Volume 2012, Article ID 126369, 8 pages doi:10.1155/2012/126369 Clinical Study Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized
More informationStephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank
From ABSORB Cohort A to ABSORB III and IV Randomized Trials Stephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank Disclosures Consultant, Abbott Vascular
More informationeluting Stents The SPIRIT Trials
Everolimus-eluting eluting Stents The SPIRIT Trials Gregg W. Stone, MD Columbia University Medical Center Cardiovascular Research Foundation Abbott XIENCE V Everolimus-eluting eluting Stent Everolimus
More informationCoronary Stent Choice in Patients With Diabetes Mellitus
Rome Cardiology Forum 2014 Coronary Stent Choice in Patients With Diabetes Mellitus Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
More informationThree-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
More informationΕνδοςτεφανιαίεσ προκζςεισ (stents):παρόν και μζλλον. Σ Χατηθμιλτιάδθσ Αναπλθρωτισ Κακθγθτισ Πανεπιςτθμιακό Νοςοκομείο ΑΧΕΠΑ
Ενδοςτεφανιαίεσ προκζςεισ (stents):παρόν και μζλλον Σ Χατηθμιλτιάδθσ Αναπλθρωτισ Κακθγθτισ Πανεπιςτθμιακό Νοςοκομείο ΑΧΕΠΑ DES Penetration -(2011) Source: Millenium Research Group Cordis has stopped manufacturing
More informationThe BIO revolution: bioadsorbable stents. Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino
The BIO revolution: bioadsorbable stents Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino BVS stent (Abbot Vascular) Strut Material: Poly-L-Lactic acid Coating Material: Poly-D,L-lactide
More informationDoes the Metal Matter?
Does the Metal Matter? An overview of next-generation stent platforms. BY LOUIS A. CANNON, MD, FSCAI, FACC, FACP; GARY A. DANIEL, MD; KRISTIN L. HOOD, PHD; AND STEVEN J. YAKUBOV, MD, FACC Originally used
More informationLong-Term Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents for Coronary Revascularization
Journal of the American College of Cardiology Vol. 57, No. 21, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.023
More informationBioresorbable Stents: Innovation or Bust?
Bioresorbable Stents: Innovation or Bust? Rajiv Jauhar, MD FACC, FSCAI Chief of Cardiology Director of Cardiac Cath Labs Northshore University Hospital San Diego July, 2016 Conflict of Interest Disclosure
More informationCOMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands
COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands TCTAP 2010 Seoul, Korea Disclosures Research Foundation of the Cardiology Department has received unrestricted research grants from:
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Byrne RA, Stone GW, Ormiston J, Kastrati A.
More informationContinuing Cardiology Education
Continuing Cardiology Education Stent selection for percutaneous coronary intervention P. D. Williams* & M. Awan James Cook University Hospital, Middlesbrough, United Kingdom Keywords Coronary artery disease,
More informationBioabsorbable Scaffolds: The Next Holy Grail?
Bioabsorbable Scaffolds: The Next Holy Grail? New Cardiovascular Horizons New Orleans, LA June 06, 2013 Lewis B. Schwartz, M.D., F.A.C.S. Vascular Surgery and Endovascular Therapy University of Chicago
More information2-year outcome of the 3-arm BIO-RESORT randomized trial in all-comer patients treated with contemporary DES
2-year outcome of the 3-arm BIO-RESORT randomized trial in all-comer patients treated with contemporary DES Marlies M. Kok, MD Thoraxcentrum Twente, MST, Enschede, the Netherlands On behalf of the BIO-RESORT
More informationDES in Diabetic Patients
DES in Diabetic Patients Charles Chan, M.D., FACC Gleneagles Hospital Singapore TCT ASIA PACIFIC 2007 Why do diabetics have worse outcome after PCI? More extensive atherosclerosis and diffuse disease Increase
More informationYukon Chrome PC. Translumina trust is what counts. Sirolimus Eluting CoCr Coronary Stent System. 5-Years Randomized Clinical Follow-Up
Sirolimus Eluting CoCr Coronary Stent System Yukon Chrome PC 5-Years Randomized Clinical Follow-Up Translumina trust is what counts trust is what counts Yukon Chrome PC DES coating with excellent long-term
More informationTLR des Stents Actifs
TLR des Stents Actifs No Conflict of Interest Target Lesion Revascularization DES vs BMS Stettler C et al. Lancet 2007;370:937-48 N=18,023 58% 70% SES vs BMS: HR=0.30 (0.24-0.37), p
More informationBiolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial
Limus Eluted From A Durable vs ERodable Stent Coating Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial Stephan
More informationTailored bifurcation therapy
Tailored bifurcation therapy Dedicated self-expanding platform that conforms to the specific bifurcation anatomy Full bifurcation lesion coverage without creating a false carina Bifurcation DES technology
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA152 drug-eluting stents for the treatment of coronary artery disease (part review of TA71) this guidance was originally
More informationInterventional cardiology has made great strides in
STEPHEN G. ELLIS, MD Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic HARIS RIAZ, MD Resident, Department of Internal Medicine, Cleveland Clinic Bioresorbable stents:
More informationCoronary Stents: Past, Present and Future
Kardiologie Kardio Lunch 07.04.2016 Coronary Stents: Past, Present and Future Christoph Kaiser Universitätsspital Basel Rubin GS, The first balloon-expandable coronary stent, University of Queensland Press
More informationIan T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FSCAI, FAPSIC MonashHeart, Monash Medical Centre & Monash University Melbourne, Australia
Final five-year clinical outcomes in the EVOLVE trial: A randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent Ian T. Meredith AM MBBS, PhD, FRACP, FCSANZ, FACC, FSCAI,
More informationCONTEMPORARY DRUG-ELUTING STENTS AND VASCULAR RESPONSE
CONTEMPORARY DRUG-ELUTING STENTS AND VASCULAR RESPONSE Anwer Habib, 1 Hiroyoshi Mori, 2 Kazuyuki Yahagi, 2 *Aloke V. Finn 2,3 1. Parkview Heart Institute, Fort Wayne, Indiana, USA 2. CVPath Institute Inc.,
More informationThe introduction of drug-eluting stents (DES) led
Stent Thrombosis With Drug-Eluting Versus Bare-Metal Stents Changing trends in the evolution of DES technology. By Usman S. Khokhar, MD, and Allen Jeremias, MD, MSc The introduction of drug-eluting stents
More informationChoice of drug-eluting stent evidence-based or empirical
Choice of drug-eluting stent evidence-based or empirical Upendra Kaul, MD DM FACC FAMS FSCAI* Aijaz H Mansoor, MD DNB (Cardiology)** ABSTRACT Percutaneous transluminal coronary angioplasty (PTCA) was developed
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationLong-term (2 5 years) adverse clinical outcomes associated with ZES versus SES, PES and EES: A Meta-Analysis
www.nature.com/scientificreports Received: 11 October 2016 Accepted: 16 June 2017 Published online: 25 July 2017 OPEN Long-term (2 5 years) adverse clinical outcomes associated with ZES versus SES, PES
More informationSCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents
SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents Christoph Varenhorst, Giovanna Sarno, Göran Olivecrona, Per Tornvall, Johan
More informationDevice and Clinical Program Highlights: SINOMED BuMA Stent
Device and Clinical Program Highlights: SINOMED BuMA Stent Runlin Gao, MD, FACC, FESC, FSCAI Fuwai Hospital, National Center for Cardiovascular Diseases, China CAMS, PUMC BuMA Supreme Platform and Pre-Clinical
More informationEluNIR. Ridaforolimus Eluting Coronary Stent System. Advancing Deliverability for the Road Ahead
Ridaforolimus Eluting Coronary Stent System Advancing Deliverability for the Road Ahead The Coronary Stent System Raising the Bar on Drug-Eluting Stent Technology Introducing the Coronary Stent System,
More informationDual-therapy stent technology for patients with coronary artery disease Kalkman, D.N.
UvA-DARE (Digital Academic Repository) Dual-therapy stent technology for patients with coronary artery disease Kalkman, D.N. Link to publication Citation for published version (APA): Kalkman, D. N. (2018).
More informationCurrent Status of BioresorbableScaffolds: Moving Forward or Backwards?
Evolving Science of Stents Current Status of BioresorbableScaffolds: Moving Forward or Backwards? Christian W. Hamm Kerckhoff Heart and Thorax Center Bad Nauheim and Medical Clinic I, University of Giessen,
More information生物可吸收支架和聚合物涂层可降解 支架能消除支架内血栓吗? 钱菊英,MD, FACC,FESC 复旦大学附属中山医院上海市心血管病研究所
生物可吸收支架和聚合物涂层可降解 支架能消除支架内血栓吗? 钱菊英,MD, FACC,FESC 复旦大学附属中山医院上海市心血管病研究所 PCI milestones Pre Post Biodegradable polymer? 1 st revolution 1977 PTCA 2 nd revolution 1988 BMS 3 rd revolution 2000 DES Bioresorbable
More informationBiodegradable Polymer Drug- Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention
Biodegradable Polymer Drug- Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention A Pooled Analysis of Individual Patient Data from ISAR-TEST
More informationEberhard Grube MD FSCAI, FACC
SCAI 30 th Annual Scientific Sessions Orlando/Fla BMS and DES Thrombosis Differences among DES Eberhard Grube MD FSCAI, FACC HELIOS Heart Center Siegburg, Siegburg, Germany Stanford University, School
More informationEvaluation of a novel stent technology: the Genous EPC capturing stent Klomp, M.
UvA-DARE (Digital Academic Repository) Evaluation of a novel stent technology: the Genous EPC capturing stent Klomp, M. Link to publication Citation for published version (APA): Klomp, M. (2012). Evaluation
More informationImpact of the Everolimus-Eluting Stent on Stent Thrombosis
Journal of the American College of Cardiology Vol. 58, No. 15, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.06.049
More informationBioMatrix TM : The New Biodegradable Abluminally Coated DES BioMatrix TM Clinical Program
BioMatrix TM : The New Biodegradable Abluminally Coated DES BioMatrix TM Clinical Program T. Santoso Univ. of Indonesia Medical School Medistra Hospital Jakarta, Indonesia Biodegradable Abluminally Coated
More informationSafety of Drug-Eluting Stents in Acute Coronary Syndromes
Rotterdam, June 11 th 2012 Safety of Drug-Eluting Stents in Acute Coronary Syndromes Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
More informationUltimaster clinical results in left main and bifurcations
Left main and complex bifurcation stenting clinical results in left main and bifurcations GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of Cardiovascular and Pulmonary Sciences
More informationBIOFLOW by Orsiro stents
BIOFLOW by stents Byeong-Keuk Kim, MD, PhD Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine Key Benefits Clinically proven
More informationHistopathological Analysis of Drug Eluting Stents in Porcine Coronary Restenosis Model
Biomaterials Research (2013) 17(2) : 062-066 Biomaterials Research C The Korean Society for Biomaterials Histopathological Analysis of Drug Eluting Stents in Porcine Coronary Restenosis Model Kyung Seob
More informationXience V (Promus) Drug-Eluting Coronary Stent
Xience V (Promus) Drug-Eluting Coronary Stent Design features, preclinical data, and clinical outcomes. BY KRISHNA SUDHIR, MD, PHD, FRACP, FACC; DAVID R. RUTLEDGE, PHARM D, FAHA, FCCP; ALENA PECHONKINA,
More informationLate-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 4, NO. 5, 2011 2011 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2010.12.014 Late-Term Clinical
More informationDrug Eluting Stents overhyped, overused and overpriced?
Advanced Angioplasty 2008 BCIS 23 rd Jan 2008 Drug Eluting Stents overhyped, overused and overpriced? William Wijns MD, PhD Cardiovascular Center Aalst http://www.cardio-aalst.be William.Wijns@village.uunet.be
More informationFor Personal Use. Copyright HMP 2014
Original Contribution Long-Term Safety and Efficacy of the Everolimus-Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice Israel M. Barbash, MD, Sa ar Minha,
More informationThe tailored solution for your bifurcation therapy
The tailored solution for your bifurcation therapy The tailored solution for your bifurcation therapy Dedicated self-expanding platform that conforms to the specific bifurcation anatomy Full bifurcation
More informationBiolimus A9 Drug-Eluting Stents: Technical Aspects and a Comprehensive Review of the EU, Asia-Pacific, and US Clinical Trial Program
TCT Asia 2006 Biolimus A9 Drug-Eluting Stents: Technical Aspects and a Comprehensive Review of the EU, Asia-Pacific, and US Clinical Trial Program Eberhard Grube MD FACC, FSCAI HELIS Heart Center Siegburg,
More informationImpact of Sex on Clinical and Angiographic Outcomes Among Patients Undergoing Revascularization With Drug-Eluting Stents
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 5, NO. 3, 2012 2012 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2011.11.011 CLINICAL RESEARCH
More informationZotarolimus- and Paclitaxel-Eluting Stents in an All-Comer Population in China
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 6, NO. 7, 2013 2013 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2013.03.001
More informationLATE AND VERY LATE STENT THROMBOSIS IN THE ERA OF SECOND-GENERATION DRUG-ELUTING STENTS
LATE AND VERY LATE STENT THROMBOSIS IN THE ERA OF SECOND-GENERATION DRUG-ELUTING STENTS Jaya Mallidi, *Amir Lotfi Division of Cardiology, Baystate Medical Center, Tufts University, Springfield, Massachusetts,
More informationDrug eluting stents. Where are we now and what can we expect in 2003? Tony Gershlick Leicester
Drug eluting stents Where are we now and what can we expect in 2003? Tony Gershlick Leicester Trials Real World What we need i. Prevent restenosis cost effective Either : - Treat all at equivalent cost
More informationDrug eluting stents From revolution to evolution. Current limitations
Drug eluting stents From revolution to evolution Current limitations Eric Eeckhout Centre Hospitalier Universitaire Vaudois Lausanne - Switzerland eric.eeckhout@chuv.ch Overview Historical perspective
More informationA Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.
A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES ISAR-TEST 2 Trial Robert A. Byrne, MB MRCPI Deutsches Herzzentrum and 1. Med.
More information2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular
More informationYukon Choice PC Translumina trust is what counts
Sirolimus Eluting Coronary Stent System 5-Years Randomized Clinical Follow-Up Translumina trust is what counts trust is what counts DES with excellent long-term clinical outcome The Translumina PC drug-eluting
More informationCoroflex ISAR. Sirolimus Eluting Polymer-Free Coronary Stent System. Vascular Systems
Coroflex ISAR Sirolimus Eluting Polymer-Free Coronary Stent System Vascular Systems Coroflex ISAR Polymer-Free Drug Coating Complete Drug Release Sirolimus Established anti-inflammatory and anti-proliferative
More informationCatch-up Phenomenon: Insights from Pathology
Catch-up Phenomenon: Insights from Pathology Michael Joner, MD CVPath Institute Inc. Gaithersburg, MD USA Path Lessons learned from the BMS and DES (1 st Gen) era Neointimal Thickness [mm] In Stent Re
More informationPaclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus
Journal of the American College of Cardiology Vol. 51, No. 7, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.10.035
More informationBéla MERKELY MD, PhD, DSc, FESC. Stent thrombosis: patophysiology, predisposing factors, definition, classification, prevention and treatment
Semmelweis University Heart Center Budapest, Hungary Béla MERKELY MD, PhD, DSc, FESC Stent thrombosis: patophysiology, predisposing factors, definition, classification, prevention and treatment 10th Interventional
More informationComparison of Everolimus-Eluting and Paclitaxel- Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 3, NO. 12, 2010 2010 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2010.09.014 Comparison
More informationIntroduction. Original Article
Original Article Clinical performance of a novel ultrathin strut, low-dose, sirolimuseluting stent with abluminal-only biodegradable polymeric coating for patients undergoing percutaneous coronary intervention
More informationOCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis?
OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis? Juan F. Granada, MD Medical Director, Skirball Center for Cardiovascular Research
More informationOCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT
OCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT Substudy Carlo Di Mario, MD Peter Barlis, MD Evelyn Regar, MD Peter Juni, MD Patrick
More informationPCI for LMCA lesions A Review of latest guidelines and relevant evidence
HCS Working Group Seminars Met Hotel, Thursday 14 th February 2013 PCI for LMCA lesions A Review of latest guidelines and relevant evidence Vassilis Spanos Interventional Cardiologist, As. Director 3 rd
More information